PPARγ Corepression Involves Alternate Ligand Conformation and Inflation of H12 Ensembles

Inverse agonists of peroxisome proliferator activated receptor γ (PPARγ) have emerged as safer alternatives to full agonists for their reduced side effects while still maintaining impressive insulin-sensitizing properties. To shed light on their molecular mechanism, we characterized the interaction...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS chemical biology 2023-05, Vol.18 (5), p.1115-1123
Hauptverfasser: Frkic, Rebecca L., Pederick, Jordan L., Horsfall, Aimee J., Jovcevski, Blagojce, Crame, Elise E., Kowalczyk, Wioleta, Pukala, Tara L., Chang, Mi Ra, Zheng, Jie, Blayo, Anne-Laure, Abell, Andrew D., Kamenecka, Theodore M., Harbort, Joshua S., Harmer, Jeffrey R., Griffin, Patrick R, Bruning, John B.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Inverse agonists of peroxisome proliferator activated receptor γ (PPARγ) have emerged as safer alternatives to full agonists for their reduced side effects while still maintaining impressive insulin-sensitizing properties. To shed light on their molecular mechanism, we characterized the interaction of the PPARγ ligand binding domain with SR10221. X-ray crystallography revealed a novel binding mode of SR10221 in the presence of a transcriptionally repressing corepressor peptide, resulting in much greater destabilization of the activation helix, H12, than without corepressor peptide. Electron paramagnetic resonance provided in-solution complementary protein dynamic data, which revealed that for SR10221-bound PPARγ, H12 adopts a plethora of conformations in the presence of corepressor peptide. Together, this provides the first direct evidence for corepressor-driven ligand conformation for PPARγ and will allow the development of safer and more effective insulin sensitizers suitable for clinical use.
ISSN:1554-8929
1554-8937
DOI:10.1021/acschembio.2c00917